Libtayo® (cemiplimab) approved by the european commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma

Tarrytown, n.y. and paris, june 25, 2021 /prnewswire/ --  approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor libtayo now approved by the european commission for three advanced cancers regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european commission (ec) has approved the pd-1 inhibitor libtayo® (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (bcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi).
REGN Ratings Summary
REGN Quant Ranking